Efficacy and safety of everolimus plus exemestane in patients with hormone receptor‐positive, HER ‐2‐negative advanced breast cancer: Results from the open‐label, multicentre, non‐interventional BRAWO study
International Journal of Cancer · 2024
DOI: 10.1002/ijc.34912 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Diana Lüftner und 16 weiteren Autor:innen. Beteiligte Einrichtung: Medical University of Brandenburg Theodor Fontane, Campus Rüdersdorf and Immanuel Hospital Märkische Schweiz, Buckow, Germany. Hauptthemen laut MEDLINE: Breast Neoplasms, Everolimus, Erb-b2 Receptor Tyrosine Kinases, Androstadienes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Novartis Deutschland GmbH, Novartis Pharma.
Abstract (Originalsprache)
BRAWO, a real‐world study, assessed the efficacy, quality of life (QoL) and safety of EVE + EXE in postmenopausal women with HR+/HER2– advanced breast cancer (ABC) in routine clinical practice. Postmenopausal women with HR+/HER2‐ABC with recurrence or progression after a NSAI were included. Primary Observation parameters included the evaluation of the effectiveness of EVE + EXE. A multivariate‐analysis using Cox proportional hazard model was built to identify predictors of progression. Overall, 2100 patients were enrolled (August 2012–December 2017); 2074 were evaluable for efficacy and safety analyses. Majority of patients (60.6%) received EVE + EXE as first (28.7%) or second‐line (31.9%) therapy. Visceral metastases were present in 54.1% patients. Median progression‐free survival (mPFS) reported as 6.6 months (95%CI: 6.3–7.0). Multivariate‐analysis in a subset of patients ( n = 1837) found higher body mass index (BMI) and non‐visceral metastases to be independent predictors of favorable PFS. Patients with a BMI of 20 to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical University of Brandenburg Theodor Fontane, Campus Rüdersdorf and Immanuel Hospital Märkische Schweiz, Buckow, Germany.
- University Hospital Heidelberg, Heidelberg, Germany.
- Division of Gynecologic Oncology, National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany.
- Department of Women's Health, Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany.
- Department of Gynecology and Obstetrics, University of Ulm, Ulm, Germany.
- German Sport University Cologne, Cologne, Germany.
ORCID-Profile: Diana Lüftner, Hans Tesch
Förderung
- Novartis Deutschland GmbH
- Novartis Pharma
Zitieren
APA
Lüftner, D., Schuetz, F., Schneeweiss, A., Hartkopf, A., Bloch, W., Decker, T., Uleer, C., Stötzer, O., Foerster, F., Schmidt, M., Mundhenke, C., Tesch, H., Jackisch, C., Fischer, T., Kreuzeder, J., Guderian, G., & Fasching, P. A. (2024). Efficacy and safety of everolimus plus exemestane in patients with hormone receptor‐positive, HER ‐2‐negative advanced breast cancer: Results from the open‐label, multicentre, non‐interventional BRAWO study. International Journal of Cancer. https://doi.org/10.1002/ijc.34912
Vancouver
Lüftner D, Schuetz F, Schneeweiss A, Hartkopf A, Bloch W, Decker T, et al. Efficacy and safety of everolimus plus exemestane in patients with hormone receptor‐positive, HER ‐2‐negative advanced breast cancer: Results from the open‐label, multicentre, non‐interventional BRAWO study. International Journal of Cancer. 2024. doi:10.1002/ijc.34912
BibTeX
@article{Lftner2024,
author = {Lüftner, Diana and Schuetz, Florian and Schneeweiss, Andreas and Hartkopf, Andreas and Bloch, Wilhelm and Decker, Thomas and Uleer, Christoph and Stötzer, Oliver and Foerster, Frank and Schmidt, Marcus and Mundhenke, Christoph and Tesch, Hans and Jackisch, Christian and Fischer, Thomas and Kreuzeder, Julia and Guderian, Gernot and Fasching, Peter A},
title = {Efficacy and safety of everolimus plus exemestane in patients with hormone receptor‐positive, HER ‐2‐negative advanced breast cancer: Results from the open‐label, multicentre, non‐interventional BRAWO study},
journal = {International Journal of Cancer},
year = {2024},
doi = {10.1002/ijc.34912}
}
EUVIMED